RecruitingNCT03792854
Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)
Sponsor
Ludwig-Maximilians - University of Munich
Enrollment
100 participants
Start Date
Dec 1, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional outcome, oncological outcome and toxicity in patients treated with definitive chemoradiation for anal cancer
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- histologically proven anal cancer without distant metastases
- indication for definitive chemoradiation therapy based on multidisciplinary evaluation
- age \>=18 years
- written informed consent
- ability to answer the standardized questionaires according to the treating physician
Exclusion Criteria4
- age \< 18 years
- prior systemic therapy with regard to anal cancer
- distant metastases
- second malignancy
Interventions
OTHEREORTC QLQ C30
standardized questionaire
OTHEREORTC QLQ CR29
standardized questionaire
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03792854
Related Trials
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT064930194 locations
Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy
NCT040944541 location
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT0407530518 locations
Detecting HPV DNA in Anal and Cervical Cancers
NCT048575282 locations
Quality of Life and Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision
NCT022808891 location